Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo device may catch more Stroke-Causing debris during artery stenting

NCT ID NCT07247864

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 03, 2026 · Updated 4 times

Summary

This study compares two methods to protect the brain during a procedure to open a narrowed neck artery (carotid stenting). The standard method uses a small filter to catch debris, but some particles may still reach the brain. The new method adds a balloon that temporarily stops blood flow and allows suction to remove debris. About 296 people with significant artery narrowing will be randomly assigned to one of the two methods. The main goal is to see if the combined approach reduces new brain spots seen on MRI within 3 days after the procedure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 296 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18 years or older; 2. Symptomatic extracranial carotid artery stenosis (occurrence of transient ischemic attack or non-disabling stroke in the ipsilateral carotid territory within the previous 6 months, with stenosis of 50% or greater) or asymptomatic extracranial carotid artery stenosis (stenosis of 70% or greater) meeting the indications for interventional treatment (stenosis degree measured by the NASCET method); 3. Pre-treatment modified Rankin Scale (mRS) score of 0 to 1; 4. Planned for stent treatment by the clinical care team; 5. Informed consent obtained from the patient or their legally authorized representative. Exclusion Criteria: 1. Occlusion or severe stenosis (70% or greater) of the intracranial segment of the ipsilateral internal carotid artery system; 2. Occlusion or severe stenosis (70% or greater) of the contralateral common carotid artery or internal carotid artery; 3. History of stenting in the head and neck vessels within 3 months; 4. Coexisting other cerebrovascular diseases, such as intracranial aneurysms greater than 5 mm or cerebrovascular malformations; 5. Onset of stroke within 7 days; 6. Large old infarctions from previous stroke that may confound the evaluation of endpoints; 7. Contraindications to magnetic resonance imaging (MRI); 8. Definite risk of cardiogenic embolism (e.g., atrial fibrillation, atrial flutter, intracardiac thrombus) or clear indications for anticoagulation therapy; 9. Absolute or relative contraindications to antiplatelet therapy; 10. Pregnant or lactating women; 11. Allergy or hypersensitivity to contrast media or stent materials (e.g., Nitinol); 12. Life expectancy less than 1 year; 13. Pre-existing neurological or psychiatric disorders (e.g., severe dementia) that would confound neurological assessments; 14. Severe renal insufficiency (eGFR less than 30 mL/min).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Carotid artery stenosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beijing Anzhen Hospital Affiliated to Capital Medical University

    RECRUITING

    Beijing, Beijing Municipality, 101118, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.